为什么用十字孢碱处理细胞 高中生物生物学理工学科
\u751f\u7269\u662f\u7406\u5de5\u5b66\u79d1\u5417\uff1f\u96be\u4e48\uff1f\u6211\u5feb\u8981\u5b66\u4e86\u5c5e\u4e8e\u7406\u79d1\uff0c\u4e0d\u96be\uff0c\u5982\u679c\u6709\u5174\u8da3\u7684\u8bdd\u80af\u5b9a\u53ef\u4ee5\u5b66\u597d\uff0c\u52a0\u6cb9\uff01
\u90a3\u4e2a\u4eba\u56de\u7b54\u7684\u633a\u597d\uff0c\u4e00\u4e2a\u4eba\u4ea7\u751f\u7684\u7cbe\u5b50\u662f\u67092\u768423\u6b21\u65b9\u79cd\u53ef\u80fd\uff0c\u4eba\u4f53\u5185\u4e0d\u6b62\u4e00\u4e2a\u7ec6\u80de\u5f62\u6210\u7cbe\u5b50\uff0c\u4f46\u662f\u6bcf\u4e2a\u7ec6\u80de\u5f62\u6210\u7684\u7cbe\u5b50\u53ea\u6709\u4e24\u79cd\uff1b\u800c\u7b2c\u4e8c\u4e2a\u56fe\uff0c\u662f\u8bb2\u7cbe\u5b50\u5f62\u6210\u8fc7\u7a0b\uff0c\u662f\u8bf4\u8fd9\u4e00\u4e2a\u7ec6\u80de\u5206\u88c2\u5f62\u6210\u7684\u7cbe\u5b50\u53ea\u67094\u4e2a\uff0c\u4e24\u79cd\u3002
湿作业安装石材时，由于水泥砂浆中水化时析出大量的氧化钙，泛到石材表面，产生不规则的花斑，俗称泛碱现象，严重影响装饰效果。因此，在石材安装前，应对石材饰面采用“防碱背涂济”进行背涂处理。十字孢碱（staurosporine）细胞凋亡诱导剂。十字孢碱 是磷脂/钙依赖蛋白酶抑制剂，能够抑制ATP的绑定
Staurosporine (antibiotic AM-2282 or STS) is a natural product originally isolated in 1977 from the bacterium Streptomyces staurosporeus.[1] It was the first of over 50 alkaloids to be isolated with this type of bis-indole chemical structure. The chemical structure of staurosporine was elucidated by X-ray analysis of a single crystal and the absolute stereochemical configuration by the same method in 1994.[2]
Staurosporine was discovered to have biological activities ranging from anti-fungal to anti-hypertensive.[3] The interest in these activities resulted in a large investigative effort in chemistry and biology and the discovery of the potential for anti-cancer treatment.
Contents
[hide]
1Biological activities
2Chemistry family
3Biosynthesis
4Research in clinical use
5List of compounds closely related to Staurosporine
6References
K252a
Stauprimide
Midostaurin
Jump up^ Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchiya H, Takahashi Y, Masuma R (1977). "A new alkaloid AM-2282 of Streptomyces origin taxonomy, fermentation, isolation and preliminary characterization". J. Antibiot. 30 (4): 275–282. doi:10.7164/antibiotics.30.275. PMID 863788.
Jump up^ Funato N, Takayanagi H, Konda Y, Toda Y, Harigaya Y, Omura S (1994). "Absolute configuration of staurosporine by X-ray analysis". Tetrahedron Lett. 35 (8): 1251–1254. doi:10.1016/0040-4039(94)88036-0.
Jump up^ [1] Rüegg UT, Burgess GM. (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends in Pharmacological Science 10 (6): 218-220.
Jump up^ Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP (2008). "A quantitative analysis of kinase inhibitor selectivity". Nat. Biotechnol. 26 (1): 127–132. doi:10.1038/nbt1358. PMID 18183025.
Jump up^ Tanramluk D, Schreyer A, Pitt WR, Blundell TL (2009). "On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine". Chem Biol Drug Des. 74 (1): 16–24. doi:10.1111/j.1747-0285.2009.00832.x. PMC 2737611 . PMID 19519740.
Jump up^ Chae HJ, Kang JS, Byun JO, Han KS, Kim DU, Oh SM, Kim HM, Chae SW, Kim HR (2000). "Molecular mechanism of staurosporine-induced apoptosis in osteoblasts". Pharmacological Research. 42 (4): 373–381. doi:10.1006/phrs.2000.0700. PMID 10987998.
Jump up^ Bruno S, Ardelt B, Skierski JS, Traganos F, Darzynkiewicz Z. (1992) Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res 52:470-473. PMID: 1728418
^ Jump up to:a b c Ryan KS (2008). "Structural studies of rebeccamycin, staurosporine, and violacein biosynthetic enzymes" (PDF). Ph.D. Thesis. Massachusetts Institute of Technology.
Jump up^ Midostaurin product page, Fermentek
Jump up^ Wang, Y; Yin, OQ; Graf, P; Kisicki, JC; Schran, H (2008). "Dose- and Time-Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes Mellitus". J Clin Pharmacol. 48 (6): 763–775. doi:10.1177/0091270008318006. PMID 18508951.
Jump up^ News Release (21 October 2013). "Study Identifies Safe Delivery System for Tricky Yet Highly Potent Anti-Cancer Compounds". UC San Diego Health System. Retrieved 27 October 2013.
Jump up^ Mukthavaram, Rajesh; Jiang, Pengei; Saklecha, Rohit; Simbery, Dmitri; Bharati, Ila; Nomura, Natsuko; Chao, Ying; Pastorino, Sandra (2013). "High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile". International Journal of Nanomedicine. Dovepress. 8 (1): 3991–4006. doi:10.2147/IJN.S51949.
Biological activities[edit]
The main biological activity of staurosporine is the inhibition of protein kinases through the prevention of ATP binding to the kinase. This is achieved through the stronger affinity of staurosporine to the ATP-binding site on the kinase. Staurosporine is a prototypical ATP-competitive kinase inhibitor in that it binds to many kinases with high affinity, though with little selectivity.[4] Structural analysis of kinase pockets demonstrated that main chain atoms which are conserved in their relative positions to staurosporine contributes to staurosporine promiscuity.[5] This lack of specificity has precluded its clinical use, but has made it a valuable research tool. In research, staurosporine is used to induce apoptosis. The mechanism of how it mediates this is not well understood. It has been found that one way in which staurosporine induces apoptosis is by activating caspase-3.[6]At lower concentration, depending on the cell type, staurosporine induces specific cell cycle effects arresting cells in G1 or G2 phases of the cycle.[7]
Chemistry family[edit]
Main article: Indolocarbazole
Staurosporine is an indolocarbazole. It belongs to the most frequently isolated group of indolocarbazoles: Indolo(2,3-a)carbazoles. Of these, Staurosporine falls within the most common subgroup, called Indolo(2,3-a)pyrrole(3,4-c)carbazoles. These fall into two classes - halogenated (chlorinated) and non-halogenated. Halogenated indolo(2,3-a)pyrrole(3,4-c)carbazoles have a fully oxidized C-7 carbon with only one indole nitrogen containing a β-glycosidic bond, while non-halogenated indolo(2,3-a)pyrrole(3,4-c)carbazoles have both indole nitrogens glycosylated, and a fully reduced C-7 carbon. Staurosporine is in the non-halogenated class.[8]
Staurosporine is the precursor of the novel protein kinase inhibitor midostaurin (PKC412).[9][10] Besides midostaurin, staurosporine is also used as a starting material in the commercial synthesis of K252c (also called staurosporine aglycone). In the natural biosynthetic pathway, K252c is a precursor of staurosporine.
Structure of an Indolo[2,3-a]pyrrole[3,4-c]carbazol
Biosynthesis[edit]
The biosynthesis of staurosporine starts with the amino acid L-tryptophan in its zwitterionic form. Tryptophan is converted to an imine by enzyme StaO which is an L-amino acid oxidase (that may be FAD dependent). The imine is acted upon by StaD to form an uncharacterized intermediate proposed to be the dimerization product between 2 imine molecules. Chromopyrrolic acid is the molecule formed from this intermediate after the loss of VioE (used in the biosynthesis of violacein – a natural product formed from a branch point in this pathway that also diverges to form rebeccamycin. An aryl aryl coupling thought to be catalyzed by a cytochrome P450 enzyme to form an aromatic ring system occurs.[8]
This is followed by a nucleophilic attack between the indole nitrogens resulting in cyclization and then decarboxylation assisted by StaC exclusively forming staurosporine aglycone or K252c. Glucose is transformed to NTP-L-ristoamine by StaA/B/E/J/I/K which is then added on to the staurosporine aglycone at 1 indole N by StaG. The StaN enzyme reorients the sugar by attaching it to the 2nd indole nitrogen into an unfavored conformation to form intermediated O-demethyl-N-demethyl-staurosporine. Lastly, O-methylation of the 4'amine by StaMA and N-methylation of the 3'-hydroxy by StaMB leads to the formation of staurosporine.[8]
Research in clinical use[edit]
When encapsulated in liposome nanoparticle, staurosporine is shown to suppress tumors in vivo in a mouse model without the toxic side effects which have prohibited its use as an anti-cancer drug with high apoptotic activity. Researchers in UC San Diego Moores Cancer Center develop a platform technology of high drug-loading efficiency by manipulating the pH environment of the cells. When injected into the mouse glioblastoma model, staurosporine is found to accumulate primarily in the tumor via fluorescence confirmation, and the mice did not suffer weight loss compared to the control mice administered with the free compound, an indicator of reduced toxicity.[11][12]
List of compounds closely related to Staurosporine[edit]
References[edit]
绛旓細绱崏绉戞鐗╂墍鍚堟垚鐨勫畨鎭閰歌鐢熺墿绱崏绱犲叿鏈夋姉鑿屻佹秷鐐庛佹姉鑲跨槫鍜屽姪浼ゅ彛鎰堝悎鐨勫姛鏁堬紝鏄涓涓氳繃妞嶇墿澶ц妯缁嗚優鍩瑰吇鑾峰緱鐨勪复搴婅嵂鐗┿傚父鐢ㄤ綔闀囬潤鍓傜殑涓滆帹鑿纰鍜岄鑼勭⒈绛夎帹鑿兎鐢熺墿纰辨槸鍦ㄨ寗绉戝ぉ浠欏瓙灞炪侀鑼勫睘銆佽帹鑿睘绛夋鐗╀腑鍚堟垚鐨勩俒6]鍏锋湁鎶楃檶鑳藉姏鐨勭传鏉夐唶鍒欐槸鐢辫８瀛愭鐗╃孩璞嗘潐鍚堟垚鐨勮悳绫诲寲鍚堢墿銆傝繖...
绛旓細宸茬‘鐭 伪榧犺偉澶缁嗚優鏉ヨ嚜楠ㄩ珦鐨勯犺澶氳兘骞茬粏鑳烇紝鍦ㄥ悇绉嶇粍缁囩殑寰幆澧冨唴鎴愮啛锛屽舰鎴愮粨缂旂粍缁囪偉澶х粏鑳炲拰绮樿啘鑲ュぇ缁嗚優銆傜粨缂旂粍缁囪偉澶х粏鑳炰綋绉緝澶э紝鑳炶川棰楃矑澶氾紝缁勮兒鍚噺楂橈紝瀵硅嵂鐗╂瘮杈冩晱鎰熴傚舰鎬佺粨鏋 鍡滅⒈鎬х矑缁嗚優鍛堝渾褰紝鐩村緞10锝14渭m锛岃優鏍稿垎鍙朵笉娓呮锛岃優璐ㄥ惈褰㈢姸涓嶈鍒欍佸ぇ灏忎笉绛夌殑鍡滅⒈鎬ч绮掞紝鐢ㄧ敳鑻兒...
绛旓細鏄吀纰卞钩琛＄殑婵绱犵粏鑳,浜轰綋鏈夊嚑濂楄皟鑺傜郴缁熸潵缁存寔鐢熺悊娲诲姩鐨勫钩琛,鍏朵腑鏈 鍏嶇柅绯荤粺鐨勫厤鐤粏鑳(鐧戒笅鎶ュ拰T\B娣嬪反缁嗚優\鍚炲櫖缁嗚優\鍙樺紓鏉浼ょ粏鑳;杩樻湁绁炵粡鍏冪粏鑳炶皟鑺傜缁忕郴缁熺殑;杩樻湁璋冭妭浣撴俯鐨勭粏鑳(涓嶇煡鍙浠涔鍚嶅瓧浜);杩樻湁閰哥⒈骞宠 鐨勫唴鍒嗘硨绯荤粺---鍡纰辩粏鑳鍜屽棞閰哥粏鑳炲氨鏄繖涓郴缁熺殑缁嗚優浜,浜烘湁鐥呮椂鍙《鏄吀鎬...
绛旓細浼戝厠锛氱敱浜庡ぇ閲忓棞纰辩粏鑳婧惰В閲婃斁澶ч噺缁勮兒锛屽彲鑳藉鑷翠紤鍏嬶紝杩欐槸涓绉嶇揣鎬ユ儏鍐点傛秷鍖栫郴缁熷苟鍙戠棁锛氬鑳冦佸崄浜屾寚鑲犳簝鐤★紝鐢氳嚦鍙兘鍙戠敓鍑鸿鍜岀┛瀛旓紝涓ラ噸濞佽儊鎮ｈ呭仴搴枫傝剳鍑鸿锛氫綔涓哄父瑙佺殑骞跺彂鐥囧拰鑷存鍘熷洜涔嬩竴锛岄渶瑕佸瘑鍒囩洃鎺у拰鍙婃椂澶勭悊銆傛澶栵紝鎰熸煋椋庨櫓杈冮珮锛岀敱浜庣櫧琛鐥呭鑷存甯哥櫧缁嗚優鍑忓皯鍜屽厤鐤姏涓嬮檷锛屾槗鎰熸煋锛屽父瑙...
绛旓細鎴愰缁嗚優纰鎬х７閰搁叾鏄湪鑳炲銆傞婧愭х⒈鎬х７閰搁叾鏄敱楠ㄨ川涓垎娉屽嚭鏉ワ紝褰撻澶翠腑閽欑洂娌夋穩涓嶈冻鏃讹紝璇ラ叾鍒嗘硨澧炲锛岄涓挋鐩愬厖瓒虫椂灏卞垎娉屽噺灏戯紝鎵浠ョ敤鏉ュ府鍔╂鏌ユ湁鏃犻挋鍚告敹涓嶈冻銆
绛旓細缁勭粐鍡滅⒈鎬缁嗚優鍦ㄧ粨缂旂粍缁囧拰绮樿啘涓婄毊鍐呮椂锛岀О鑲ュぇ缁嗚優锛屽叾缁撴瀯鍜屽姛鑳戒笌鍡滅⒈鎬х粏鑳炵浉浼笺
绛旓細楂樸傝幉蹇纰辩粏鑳鏈夎緝寮虹殑闄嶅帇浣滅敤锛岃繕鍏锋湁鎶楀绉嶅疄楠屾у績寰嬪け甯搞佹墿寮犺剳琛绠°佹姉蹇冭倢缂鸿鍜岄槻姝侀嗚浆琛绠″钩婊戣倢缁嗚優澧炴畺浣滅敤锛屾按骞抽珮銆傝幉蹇冪⒈鏄竴绉嶅弻鑻勫熀鍥涙阿寮傚柟鍟夌敓鐗╃⒈銆傚叾鍒嗗瓙寮忎负C??H??N?O?銆
绛旓細鍡滅⒈鎬х矑缁嗚優鍑忓皯锛氬棞纰辨х矑缁嗚優鍦ㄥ鍛ㄨ涓弬鑰冨煎緢浣庯紝鏁呭叾鍑忓皯鏃犱复搴婃剰涔夈傚棞纰辨х偣褰╃孩缁嗚優璁℃暟 Baso锛峱hilicstipplingerythrocyte count 鍙栨墜鎸囪鍒跺琛娑傜墖 姝ょ缁嗚優灞炰簬灏氭湭瀹屽叏鎴愮啛鐨勭孩缁嗚優锛屾甯镐汉琛鐗囦腑鏋佸皯瑙佸埌銆傚湪绾㈢粏鑳炲啀鐢熷姞閫燂紝涓旀湁绱婁贡鐜拌薄鏃讹紝鍙兘鍥犱负鑳炴祮涓殑鏍哥硸浣撳彂鐢熻仛闆嗗彉鎬у悗鐫鑹叉墍鑷...
绛旓細鍡滈吀鎬缁嗚優鏄寚鑳炶川鍛堝棞閰告х殑缁嗚優銆傚寘鎷: (1)鐢熼暱婵绱犵粏鑳 somatotroph (2)鍌钩婵绱犵粏鑳瀖ammotroph 鍡滅⒈鎬х粏鑳 瀹氫箟1:鍚棞纰辨ч绮掔殑鐧界粏鑳炪傚鍛ㄨ涓暟閲忛氬父浣庝簬1%,琛ㄨ揪楂樹翰鍜屽姏IgE Fc鍙椾綋,鑳界壒寮傛х粨鍚圛gE,鍦ㄧ値鐥囨垨I鍨嬭秴鏁忓弽搴斾腑,鑳介氳繃鑴遍绮掕岃繀閫 ...
绛旓細鍒╃敤宸ヤ笟鍙戦叺鍚庡墿浣欑殑鑺藉鏉嗚弻鑿屼綋鎴栭叺姣嶈弻鍚搁檮閲嶉噾灞烇紝鍏蜂綋鍋氭硶鏄鍏鐢ㄧ⒈澶勭悊鑿屼綋锛屼互渚垮鍔犲叾鍚搁檮閲嶉噾灞炵殑鑳藉姏銆傜劧鍚庨氳繃鍖栧浜よ仈娉曞浐瀹氳繖浜缁嗚優锛屽浐瀹氬寲鐨勮娊瀛㈡潌鑿屽閲嶉噾灞炵殑鍚搁檮娌℃湁閫夋嫨鎬э紙寰敓鐗╁湪缁撳悎鏃犳満姹℃煋鐗╀笂琛ㄧ幇鍑洪夋嫨鎬э紝澶氫簬澶у鏁板悎鎴愮殑鍖栧鍚搁檮鍓傦紝寰敓鐗╁閲戝睘鐨勫惛闄勫拰绱Н涓昏鍙栧喅浜庝笉鍚...
